Back to search results

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v8

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic in Arizona, Scottsdale, Arizona, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Tanios S. Bekaii-Saab, MD)

  • Mayo Clinic in Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Umair Majeed, MD)

  • Mayo Clinic in Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Ryan M. Carr, MD, PhD)
Study leads

  • Tanios S. Bekaii-Saab, MD

    Principal Investigator

    Mayo Clinic

View source on ClinicalTrials.gov(opens in a new tab)